// App-Quantinova.ai

e24065 : Applications of liquid biopsies as prognostic markers in patients (pts) with advanced ovarian cancer (AOC) on metronomic cyclophosphamide (MCy) with or without nintedanib (N) (Trans METRO-BIBF).

Researchers

Presenter

  • Marcia Hall

Principal Investigators

  • Dimple Chudasama

  • Charlotte Roberts

  • Nick Stone

  • Martha Vardaki

  • Howard Urnowitz

  • Ekkhard Schuetz

  • Julia Beck

  • Emmanouil Karteris

Medical Centers

  • Mount Vernon Cancer Centre, Middlesex, United Kingdom

  • Brunel University, Uxbridge, United Kingdom

  • Mount Vernon Cancer Centre, Northwood, United Kingdom

  • The University of Exeter Mail Room,, Exeter, United Kingdom

  • Chronix Biomedical, Gottingen, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Circulating DNA

Drug/Treatment

  • calcium/fluoride

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Nintedanib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved